| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Dechant Robert Thomas | Chief Executive Officer, Director | C/O IBEX LIMITED, 1717 PENNSYLVANIA AVENUE NW, SUITE 825, WASHINGTON | Lisa Lenstrohm, Attorney-in-Fact | 27 Feb 2026 | 0001298255 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IBEX | Common Shares | Award | $0 | +18,000 | +6.5% | $0.000000 | 293,406 | 26 Feb 2026 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. 25% of the RSUs vest on July 1, 2026, with 25% of the RSUs vesting annually thereafter for the following three years, provided that the Reporting Person remains in continuous service on each vesting date. Unless otherwise provided, on each vesting date shares of Common Stock will automatically be withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. |